Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2014, XXIX/171: 149-152 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2014, XXIX/171: 149-152

Title: Neurohormonal effects following treatment with dopamine. More advantages or disadvantages?  

Authors: Mysiak A., Kobusiak-Prokopowicz M., Kucharski T., Kleczyk R.

More details

01/171

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Neurohormonal effects following treatment with dopamine. More advantages or disadvantages?


Mysiak A., Kobusiak-Prokopowicz M., Kucharski T., Kleczyk R.

Medical University of Wrocław, Poland, Chair and Department of Cardiology

Due to a big amount of dopaminergic receptors set in the vertebrate central nervous system (CNS), endogenously freed dopamine determines motor and cognitive activities of an organism. It influences neurohormonal regulation of the body, among all, other catecholamines' production; it also regulates kidney's functioning, the cardiovascular system and alimentary canal. Dopamine (a natural catecholamine) containing specimens are often used for the sake of intensive medical care. A particular effect, which is natriuretic, inotropic and vasopresive, is expected under inpatient treatment conditions depending on a selected dose. In practice, however, a potential influence of such treatment on neurohormonal processes, among all, an impact on hypothalamo–hypophyseal–adrenal axis is rarely taken into account. Considering numerous adverse events, a risk of renal failure development and blood redistribution disorders in the mucous membrane of the gastrointestinal tract, a negative impact on the respiratory system, as well as in the event of insufficient evidence for dopamine's effectiveness in both prevention and acute renal failure) treatment, dopamine’s implementaion in so called diuretic doses is controversial. Its implementaion as a drug with the vasopressor effect must be reconsidered and individualised.

Key words: dopamine, hypothalamo–hypophyseal–adrenal axis, intensive care, nephroprotection, diuretic drugs

Pol. Merk. Lek., 2010, XXIX, 171, 149